Toprol Antitrust Litigation — In re Metoprolol Succinate End-Payor Antitrust Litigation

Court: United States District Court, District of Delaware

Case No.: 06-71GMS

WBE represented the United Association of Plumbers and Pipefitters Local 572 and served as co-chair of the discovery committee in this antitrust class action brought against AstraZeneca LP and various related drug companies by third-party payors and consumers of the heart medication Toprol XL.  The case alleged that, in violation of federal antitrust laws, as well as state unfair competition laws, AstraZeneca improperly manipulated patent filings and filed baseless patent infringement lawsuits in an effort to prevent market entry of generic versions of the drug Toprol-XL.  On March 7, 2013, Judge Mary Pat Thynge granted final approval to a settlement that resulted in AstraZeneca paying up to $11 million to consumers and third-party payors who purchased Toprol XL or its generic, metoprolol succinate.

 

News Articles

WBE Ranked in Chambers & Partners 2026 USA Spotlight

WBE is proud to announce the firm has been ranked for the second year by Chambers & Partners in their Spotlight Illinois guide. WBE was recognized for our work in General Litigation, and is ...

Court Grants Final Approval of $2.25 Million Settlement in Effexor XR Antitrust Litigation

On Tuesday, August 19, 2025, United States District Judge Zahid N. Quraishi of the District of New Jersey granted final approval of Indirect Purchaser Plaintiffs’ $2.25 million class-action ...

Court Grants Plaintiffs’ Motion for Summary Judgment in Part in Actos Antitrust Litigation

On Monday, March 31, 2025, U.S. District Court Judge Ronnie Abrams of the Southern District of New York partially granted summary judgment to two classes of Plaintiffs who purchased the diabetes ...
No results found.